KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $131.4 million.

  • Recursion Pharmaceuticals' Net Cash Flow rose 377.72% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.8 million, marking a year-over-year increase of 469.36%. This contributed to the annual value of $205.0 million for FY2024, which is 229.85% up from last year.
  • Recursion Pharmaceuticals' Net Cash Flow amounted to $131.4 million in Q3 2025, which was up 751.62% from $15.4 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Cash Flow peaked at $423.8 million during Q2 2021, and registered a low of -$238.0 million during Q3 2021.
  • Moreover, its 3-year median value for Net Cash Flow was -$19.5 million (2023), whereas its average is $8.7 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Net Cash Flow tumbled by 2,600.26% in 2023 and then skyrocketed by 4,068.66% in 2024.
  • Recursion Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$109.6 million in 2021, then spiked by 186.25% to $94.5 million in 2022, then tumbled by 95.67% to $4.1 million in 2023, then skyrocketed by 4,068.66% to $170.7 million in 2024, then skyrocketed by 377.72% to $131.4 million in 2025.
  • Its Net Cash Flow stands at $131.4 million for Q3 2025, versus $15.4 million for Q2 2025 and -$98.7 million for Q1 2025.